Compare Bristol-Myers Squibb Co (BMY) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares Global Clean Energy ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while iShares Global Clean Energy ETF trades at $18.2. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares Global Clean Energy ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| BMY | ICLN | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | — |
52-Week High | $65.89 | $23.75 |
52-Week Low | $42.60 | $13.66 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
ICLN is trading at $18.395, up 1.74% today, with a bearish technical signal from moving averages. The ETF provides exposure to 105 global renewable energy companies but faces competition from traditional energy ETFs offering lower fees and higher yields. Recent news highlights clean energy's 25% gains in 2026, though policy uncertainties and geopolitical tensions pose risks.
The outlook remains mixed with structural growth in clean energy demand balanced against regulatory headwinds and expense ratio disadvantages. Key opportunities include global energy transition trends, while risks involve U.S. permit delays and Chinese supply chain tensions affecting solar development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
